Hepatitis C virus RNA is 5'-capped with flavin adenine dinucleotide

丙型肝炎病毒RNA的5'端带有黄素腺嘌呤二核苷酸帽。

阅读:22
作者:Anna V Sherwood #,Lizandro R Rivera-Rangel #,Line A Ryberg,Helena S Larsen,Klara M Anker,Rui Costa,Cathrine B Vågbø,Eva Jakljevič,Long V Pham,Carlota Fernandez-Antunez,Gabriele Indrisiunaite,Agnieszka Podolska-Charlery,Julius E R Grothen,Nicklas W Langvad,Nicolas Fossat,Anna Offersgaard,Amal Al-Chaer,Louise Nielsen,Anna Kuśnierczyk,Christina Sølund,Nina Weis,Judith M Gottwein,Kenn Holmbeck,Sandro Bottaro,Santseharay Ramirez,Jens Bukh,Troels K H Scheel,Jeppe Vinther

Abstract

RNA viruses have evolved elaborate strategies to protect their genomes, including 5' capping. However, until now no RNA 5' cap has been identified for hepatitis C virus1,2 (HCV), which causes chronic infection, liver cirrhosis and cancer3. Here we demonstrate that the cellular metabolite flavin adenine dinucleotide (FAD) is used as a non-canonical initiating nucleotide by the viral RNA-dependent RNA polymerase, resulting in a 5'-FAD cap on the HCV RNA. The HCV FAD-capping frequency is around 75%, which is the highest observed for any RNA metabolite cap across all kingdoms of life4-8. FAD capping is conserved among HCV isolates for the replication-intermediate negative strand and partially for the positive strand. It is also observed in vivo on HCV RNA isolated from patient samples and from the liver and serum of a human liver chimeric mouse model. Furthermore, we show that 5'-FAD capping protects RNA from RIG-I mediated innate immune recognition but does not stabilize the HCV RNA. These results establish capping with cellular metabolites as a novel viral RNA-capping strategy, which could be used by other viruses and affect anti-viral treatment outcomes and persistence of infection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。